Skip to content

Asthma in children

TL;DR — Childhood asthma is not adult asthma at smaller scale. Preschool wheeze is common and heterogeneous, objective testing is often unavailable, drug delivery depends on caregiver and device, and the balance between attack prevention and treatment burden changes with development. In preschool recurrent wheeze, daily ICS reduces systemic-steroid-requiring exacerbations versus placebo (RR 0.70, 95% CI 0.61–0.79; NNT 9), with phenotype-dependent alternatives for intermittent viral-triggered disease (Kaiser 2016, PMID 27230765). Long-term ICS reduces attacks but slows first-year growth by roughly 0.5 cm/year on average; adult-height effect in the strongest long-term trial was about −1.2 cm (Loke 2015, PMID 26191797). Diagnosis should be periodically revisited, technique demonstrated by child and caregiver, and school access, smoke exposure, cost and inequity treated as clinical variables.

Age changes the problem

Developmental group Central uncertainty Useful evidence Common error
Infant Wheeze may be bronchiolitis, airway anatomy or another disorder Pattern, feeding/growth, hypoxemia, focal signs Calling first viral wheeze asthma
Preschool Episodic wheeze may remit or become persistent asthma Recurrent pattern, interval symptoms, atopy/eosinophils, treatment response Treating phenotype labels as stable diagnoses
School age Variable airflow can usually be tested Spirometry with bronchodilator; repeat if initially normal Diagnosing from cough alone
Adolescent Adherence, autonomy, stigma and competing diagnoses dominate Private history, objective adherence, spirometry, exercise/laryngeal assessment Speaking only to caregiver

Preschool wheeze is a working syndrome

About half of children wheeze by age six, but only a subset develops persistent asthma (Kaiser 2016, PMID 27230765). “Episodic viral” and “multiple-trigger” wheeze are clinically intuitive labels, yet children move between them and caregiver reports do not reliably map to stable mechanisms (Schultz 2011, PMID 21722843; Ducharme 2014, PMID 24792856).

Birth-cohort analyses identify multiple trajectories—transient early, intermediate/late onset and persistent patterns—but data-driven classes depend on ages sampled and definitions used (Dai 2022, PMID 34974064; Owora 2021, PMID 32668501). These trajectories describe populations; they do not determine an individual child’s future.

Rhinovirus-associated bronchiolitis carries a stronger later association than RSV bronchiolitis: pooled odds of recurrent wheeze were OR 4.11 (95% CI 2.24–7.56) for rhinovirus versus RSV groups, though viral detection, confounding by host susceptibility and diagnostic overlap limit causal inference (Makrinioti 2022, PMID 35338734).

Features that increase the probability of persistent asthma

Feature Interpretation
Wheeze apart from colds More consistent with persistent airway disease
Atopic dermatitis or allergen sensitization Supports type-2 susceptibility, not diagnostic alone
Parent with asthma Raises prior probability
Blood eosinophilia Enriches for ICS-responsive biology; thresholds are context-specific
Severe/frequent episodes Predicts future healthcare use and persistence
Reduced lung function when measurable Makes later persistence/remodeling more likely

Prediction models for school-age asthma have variable definitions, validation and transportability; they are better for risk discussion and research enrichment than for withholding treatment from a symptomatic child (Kothalawala 2020, PMID 32181536; Smit 2015, PMID 26597131).

Diagnosis

The diagnosis combines a compatible recurrent symptom pattern, exclusion of alternatives and evidence of variable airflow where age permits. Systematic review found substantial variation among infant/preschool guidelines, reflecting limited direct evidence rather than a single reliable test (Moral 2019, PMID 30193886).

For a cooperative child, obtain spirometry before and after bronchodilator. Normal spirometry between episodes does not exclude asthma; repeat during symptoms, examine variability or use a suitable challenge test. Bronchodilator response evidence in preschool children is heterogeneous and cannot supply a universal threshold independent of technique and reference equations (Raywood 2016, PMID 27273556).

Think beyond asthma when

  • symptoms begin in the neonatal period;
  • cough or wheeze is persistently focal;
  • there is stridor, choking, swallowing dysfunction or recurrent focal pneumonia;
  • growth falters or there is chronic wet cough, clubbing or hypoxemia;
  • bronchodilator/controller trials produce no reproducible benefit despite verified delivery;
  • exertional dyspnea has inspiratory noise, abrupt onset/offset or normal airflow during symptoms.

Relevant alternatives include airway malacia, vascular ring, aspirated foreign body, cystic fibrosis, primary ciliary dyskinesia, bronchiectasis, aspiration, immunodeficiency, inducible laryngeal obstruction and dysfunctional breathing.

Controller treatment

ICS is first-line anti-inflammatory therapy for persistent childhood asthma. Treatment intensity should reflect both impairment and future attack risk, then be adjusted after technique, adherence, exposure and diagnosis are reviewed.

Preschool recurrent wheeze

A meta-analysis of 22 trials and 4,550 children found daily medium-dose ICS reduced systemic-steroid-requiring exacerbations versus placebo, RR 0.70 (95% CI 0.61–0.79; NNT 9). In persistent-asthma subgroups, RR was 0.56 (0.46–0.70; NNT 11); daily ICS also outperformed montelukast in one trial, RR 0.59 (0.38–0.92) (Kaiser 2016, PMID 27230765).

In 278 high-risk preschool children with recurrent wheeze and low interval impairment, daily low-dose and illness-initiated intermittent high-dose budesonide produced similar oral-steroid-requiring exacerbation rates: 0.97 (95% CI 0.76–1.22) versus 0.95 (0.75–1.20) per patient-year, with lower cumulative exposure in the intermittent group (Zeiger 2011, PMID 22111718).

This does not make the regimens interchangeable for every child. Daily treatment fits persistent symptoms; pre-emptive intermittent high-dose ICS may fit selected children with clearly recognized viral episodes, a reliable caregiver plan and little interval impairment. Repeated high-dose courses still carry systemic exposure.

School-age asthma

Situation after confirmation Typical strategy Monitoring emphasis
Infrequent symptoms, attack risk present Age-appropriate ICS-containing reliever or ICS whenever reliever is taken, per local approval/guideline Attacks and actual ICS delivery
Persistent symptoms Daily low-dose ICS plus reliever Control, technique, growth and attacks
Uncontrolled on low-dose ICS Verify delivery; consider ICS/LABA or regimen-specific MART where approved Adherence before dose escalation
Persistent attacks on optimized therapy Specialist phenotype and severe-asthma assessment Comorbidity, biomarkers, systemic steroid burden

The CARE trial randomized 360 children aged 5–15 years using SABA alone. As-needed budesonide–formoterol reduced annual attacks from 0.41 to 0.23 per participant-year versus salbutamol, relative rate 0.55 (95% CI 0.35–0.86); it was open-label and its specific low-dose formulation and regulatory availability matter (Hatter 2025, PMID 41033330).

Evidence for as-needed combination relievers is much richer in adults than young children. Do not extrapolate dose, maximum daily actuations or device competence across ages without formulation-specific guidance (Crossingham 2021, PMID 33945639).

Montelukast improves symptoms versus placebo but ICS gives better daytime and nocturnal symptom control on average (Mayoral 2023, PMID 37852659). Discuss possible neuropsychiatric adverse effects and reassess benefit rather than allowing indefinite default use.

What long-term trials show

CAMP randomized 1,041 children aged 5–12 years for four to six years. Budesonide did not change the primary post-bronchodilator FEV1-growth outcome, but reduced hospitalizations from 4.4 to 2.5 per 100 person-years and urgent visits from 22 to 12 per 100 person-years versus placebo (PMID 11027739).

In PEAK, 285 high-risk children aged 2–3 years received fluticasone or placebo for two years followed by a treatment-free year. ICS improved episode-free days and attacks during treatment, but benefit did not persist after withdrawal; height gain was 1.1 cm less at 24 months and 0.7 cm less by trial end (Guilbert 2006, PMID 16687711).

The conclusion is important: current controllers suppress disease activity; they have not been shown to prevent asthma simply by being started early in high-risk preschoolers.

Growth and systemic safety

Across 16 RCTs, more than 12 months of ICS reduced first-year growth velocity by 0.48 cm/year (95% CI 0.29–0.66). The best adult-height RCT estimate was −1.20 cm (−1.90 to −0.50) with budesonide versus placebo (Loke 2015, PMID 26191797).

A Cochrane review likewise found a small average first-year linear-growth reduction, varying by molecule and study; effect is most pronounced early and is not a reason to leave asthma uncontrolled (Zhang 2014, PMID 25164572). Dose-response evidence supports using the minimum dose that maintains control (Pruteanu 2014, PMID 25030199).

Monitor Why Response to concern
Height plotted longitudinally Trend matters more than one measure Verify measurement; review dose and disease control
Cumulative systemic steroids Bursts add metabolic, bone and adrenal risk Improve prevention; specialist review for recurrence
Symptoms of adrenal suppression Rare but serious at high exposure/interactions Urgent endocrine evaluation when suspected
Oropharynx/voice Local deposition effects Technique, spacer where appropriate, mouth rinse

Poorly controlled asthma itself impairs sleep, activity, nutrition and growth and exposes children to systemic corticosteroids. The valid comparison is the lowest effective ICS dose versus the morbidity and treatment burden of uncontrolled disease.

Acute preschool wheeze

Bronchodilator treatment, oxygen for hypoxemia and severity-based escalation remain central. Oral corticosteroid benefit is less uniform than in established school-age asthma. An individual-participant-data meta-analysis found modest early improvement and shorter length of stay overall, with larger benefit in children with prior wheeze/asthma, but vomiting risk increased (Lee 2024, PMID 38527486).

Repeated antibiotic treatment is not routine asthma care. Fever, focal findings or another supported bacterial diagnosis should drive antibiotics, not wheeze alone.

Device, family and school system

Young children usually need an MDI with spacer and well-fitting facemask; transition to mouthpiece only when seal and breathing sequence are reliable. Observe both child and caregiver. Technique is generally poor in pediatric studies and improves with repeated counseling (Gillette 2016, PMID 27130811).

At school, safety requires:

  • immediately accessible rescue medication under local policy;
  • a current action plan shared with authorized staff;
  • permission and competence for self-carry when developmentally appropriate;
  • a plan for exercise, trips and medication expiry;
  • protection from smoke, vaping and known occupational/classroom triggers;
  • a pathway after an attack rather than automatic exclusion from activity.

School self-management interventions reduced ED visits, OR 0.70 (95% CI 0.53–0.92), and produced a small hospitalization reduction, SMD −0.19 (−0.35 to −0.04) (Kneale 2019, PMID 30686788). School telemedicine can improve access, but intervention components and equity effects differ (Kim 2020, PMID 32446856).

Adolescence and transition

Interview the adolescent for part of the visit without the caregiver when appropriate. Ask directly about vaping/smoking, medication beliefs, mood, sports, menstruation, work, cost and whether inhaler use feels embarrassing. Demonstrate confidentiality boundaries.

Transition planning should cover prescription ownership, refill navigation, action-plan use, device mastery, emergency contacts and transfer of objective diagnostic records. An apparent increase in “severity” during adolescence often warrants renewed attention to adherence, environment and inducible laryngeal obstruction.

Prognosis

In an administrative birth cohort of 34,216 children diagnosed before age six, 48.6% had no asthma healthcare encounters by age 12; hospitalization in the first year after diagnosis tripled the odds of persistence (To 2007, PMID 18056566). Healthcare-use remission is not the same as physiological remission.

Among 879 CAMP participants, 26% met a clinical remission definition in early adulthood and 15% met a stricter definition including normal airway responsiveness. Baseline FEV1/FVC was the strongest predictor (Wang 2019, PMID 30445065).

Childhood asthma and low lung-function trajectories can contribute to later fixed obstruction. A cohort followed to age 53 identified distinct trajectories, with childhood asthma, bronchitis, pneumonia, allergic disease, smoking and maternal smoking among determinants of adverse pathways and later COPD risk (Bui 2018, PMID 29628376).

Open questions

  • Which preschool biological markers can select daily versus illness-initiated ICS prospectively? (Kaiser 2016, PMID 27230765)
  • Can early intervention alter natural history rather than only suppress symptoms during treatment? (Guilbert 2006, PMID 16687711)
  • What are the safest and most effective ICS-containing reliever strategies below age 12 across available formulations? (Hatter 2025, PMID 41033330)
  • How should growth, adrenal risk and cumulative oral-steroid exposure be combined into one safety metric?
  • Which school and digital programs close rather than widen socioeconomic disparities?

References

  1. Kaiser SV, et al. Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. Pediatrics. 2016. PMID 27230765
  2. Schultz A, Brand PL. Episodic viral wheeze and multiple-trigger wheeze in preschool children. Paediatr Respir Rev. 2011. PMID 21722843
  3. Ducharme FM, et al. Diagnosis, management, and prognosis of preschool wheeze. Lancet. 2014. PMID 24792856
  4. Dai R, et al. Wheeze trajectories in the CHILD cohort study. J Allergy Clin Immunol. 2022. PMID 34974064
  5. Owora AH, Zhang Y. Childhood wheeze trajectory-specific risk factors: systematic review and meta-analysis. Pediatr Allergy Immunol. 2021. PMID 32668501
  6. Makrinioti H, et al. RSV- and rhinovirus-induced bronchiolitis and later wheeze/asthma. Pediatr Allergy Immunol. 2022. PMID 35338734
  7. Kothalawala DM, et al. Prediction models for childhood asthma: systematic review. Pediatr Allergy Immunol. 2020. PMID 32181536
  8. Smit HA, et al. Childhood asthma prediction models: systematic review. J Asthma. 2015. PMID 26597131
  9. Moral L, et al. Asthma diagnosis in infants and preschool children: systematic review of guidelines. Allergol Immunopathol. 2019. PMID 30193886
  10. Raywood E, et al. Bronchodilator response in preschool children: systematic review. Pediatr Pulmonol. 2016. PMID 27273556
  11. Zeiger RS, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. 2011. PMID 22111718
  12. Hatter L, et al. Budesonide-formoterol versus salbutamol reliever therapy in children: CARE. Lancet. 2025. PMID 41033330
  13. Crossingham I, et al. Fixed-dose beta agonist and steroid inhaler as required for mild asthma. Cochrane Database Syst Rev. 2021. PMID 33945639
  14. Mayoral K, et al. Montelukast in paediatric asthma and allergic rhinitis: systematic review and meta-analysis. Eur Respir Rev. 2023. PMID 37852659
  15. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children. N Engl J Med. 2000. PMID 11027739
  16. Guilbert TW, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006. PMID 16687711
  17. Loke YK, et al. Impact of inhaled corticosteroids on growth in children: systematic review and meta-analysis. PLoS One. 2015. PMID 26191797
  18. Zhang L, et al. Effect of inhaled corticosteroids on linear growth in children. Cochrane Database Syst Rev. 2014. PMID 25164572
  19. Pruteanu AI, et al. ICS dose-response effects on growth in children. Cochrane Database Syst Rev. 2014. PMID 25030199
  20. Lee B, et al. Oral corticosteroids for acute preschool wheeze: individual-participant-data meta-analysis. Lancet Respir Med. 2024. PMID 38527486
  21. Gillette C, et al. Inhaler technique in children with asthma: systematic review. Acad Pediatr. 2016. PMID 27130811
  22. Kneale D, et al. School-based self-management interventions: Cochrane review and meta-analysis. Thorax. 2019. PMID 30686788
  23. Kim CH, et al. School-based telemedicine interventions for asthma: systematic review. Acad Pediatr. 2020. PMID 32446856
  24. To T, et al. Persistence and remission in childhood asthma: population-based cohort. Arch Pediatr Adolesc Med. 2007. PMID 18056566
  25. Wang AL, et al. Remission of persistent childhood asthma: early predictors of adult outcomes. J Allergy Clin Immunol. 2019. PMID 30445065
  26. Bui DS, et al. Childhood predictors of lung-function trajectories and future COPD risk. Lancet Respir Med. 2018. PMID 29628376